Rimonabant in obesity
This presentation is the property of its rightful owner.
Sponsored Links
1 / 5

Rimonabant in Obesity PowerPoint PPT Presentation


  • 40 Views
  • Uploaded on
  • Presentation posted in: General

RIO LIPIDS Trial. Rimonabant in Obesity. Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Jean-Pierre Despres. RIO LIPIDS Trial. 1,036 patients with abdominal obesity and abnormal lipid profiles Randomized, double-blind, multicenter. Rimonabant

Download Presentation

Rimonabant in Obesity

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Rimonabant in obesity

RIO LIPIDS Trial

Rimonabant in Obesity

Presented at

American College of Cardiology

Scientific Sessions 2004

Presented by Dr. Jean-Pierre Despres


Rio lipids trial

RIO LIPIDS Trial

1,036 patients with abdominal obesity and

abnormal lipid profiles

Randomized, double-blind, multicenter

  • Rimonabant

  • A selective cannabinoid type 1 receptor antagonist

  • 20 mg

  • n=346

  • Rimonabant

  • A selective cannabinoid type 1 receptor antagonist

  • 5 mg

  • n=345

  • Placebo

  • n=342

Treatment for 1 Year

  • Endpoints (1 year):

    • Weight loss 5% of body weight and 10% of body weight

    • Change in lipid profile

Presented at ACC Scientific Sessions 2004


Rio lipids trial1

RIO LIPIDS Trial

Weight Loss 5%

p < 0.001 for high-dose vs placebo

Weight Loss 10%

p < 0.001 for high-dose vs placebo

Presented at ACC Scientific Sessions 2004


Rio lipids trial2

RIO LIPIDS Trial

Relative Reduction in CRP

p=0.007 for rimonabant 20 mg vs placebo

  • C-reactive protein reduction greater in rimonabant 20 mg arm compared with placebo (from 3.7 to 2.7 mg/l with rimonabant 20 mg vs. 3.6 to 3.2 mg/l with placebo, p=0.007)

  • HDL increased 23% and triglycerides decreased 15% in rimonabant 20 mg, but no significant difference in LDL levels

Presented at ACC Scientific Sessions 2004


Rio lipids trial3

RIO LIPIDS Trial

  • Among patients with abdominal obesity and abnormal lipid profiles, use of the selective cannabinoid type 1 receptor antagonist rimonabant in a 5 mg or 20 mg dose was associated with greater weight reduction after 1 year of treatment compared with placebo

  • Additional benefits were observed in HDL and triglyceride levels with rimonabant

  • Obesity is a growing epidemic, which has been shown to contribute to a variety of co-morbidities, including increased coronary heart disease, diabetes, and hyperlipidemia

  • Few pharmacologic agents have been identified as both safe and effective in reducing weight, pointing to the potential importance of the present study

  • Further evaluation is warranted


  • Login